» Articles » PMID: 9746786

Stem Cell Factor As a Single Agent Induces Selective Proliferation of the Philadelphia Chromosome Positive Fraction of Chronic Myeloid Leukemia CD34(+) Cells

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1998 Sep 25
PMID 9746786
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction between p145(c-KIT) and p210(bcr-abl) in transduced cell lines, and the selective outgrowth of normal progenitors during long-term culture of chronic myeloid leukemia (CML) cells on stroma deficient in stem-cell factor (SCF) suggests that the response of CML cells to SCF may be abnormal. We examined the proliferative effect of SCF(100 ng/mL), provided as the sole stimulus, on individual CD34(+) cells from five normal donors and five chronic-phase CML patients. Forty-eight percent of isolated single CML CD34(+) cells proliferated after 6 days of culture to a mean of 18 cells, whereas only 8% of normal CD34(+) cells proliferated (mean number of cells generated was 4). SCF, as a single agent, supported the survival and expansion of colony-forming unit-granulocyte-macrophage (CFU-GM) from CML CD34(+)CD38(+) cells and the more primitive CML CD34(+)CD38(-) cells. These CFU-GM colonies were all bcr-abl positive, showing the specificity of SCF stimulation for the leukemic cell population. Coculture of CML and normal CD34(+) cells showed exclusive growth of Ph+ cells, suggesting that growth in SCF alone is not dependent on secretion of cytokines by CML cells. SCF augmentation of beta1-integrin-mediated adhesion of CML CD34(+) cells to fibronectin was not increased when compared with the effect on normal CD34(+) cells, suggesting that the proliferative and adhesive responses resulting from SCF stimulation are uncoupled. The increased proliferation may contribute to the accumulation of leukemic progenitors, which is a feature of CML.

Citing Articles

targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration.

Su R, Li C, Wang X, Li Z, Wen Z, Yin Z Mol Ther Nucleic Acids. 2023; 32:729-742.

PMID: 37234746 PMC: 10208829. DOI: 10.1016/j.omtn.2023.04.026.


Low c-Kit expression identifies primitive, therapy-resistant CML stem cells.

Shah M, Kumar H, Qiu S, Li H, Harris M, He J JCI Insight. 2022; 8(1).

PMID: 36413413 PMC: 9870079. DOI: 10.1172/jci.insight.157421.


MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.

Zhao H, Pomicter A, Eiring A, Franzini A, Ahmann J, Hwang J Blood. 2021; 139(5):761-778.

PMID: 34780648 PMC: 8814676. DOI: 10.1182/blood.2021011802.


The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.

Zhan H, Lin C, Segal Y, Kaushansky K Leukemia. 2017; 32(2):462-469.

PMID: 28744010 PMC: 5783797. DOI: 10.1038/leu.2017.233.


KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Corbin A, OHare T, Gu Z, Kraft I, Eiring A, Khorashad J Cancer Res. 2013; 73(18):5775-86.

PMID: 23887971 PMC: 3894913. DOI: 10.1158/0008-5472.CAN-13-1318.